Do any peptides work orally without help?

Very few, and generally only small, unusually rigid ones such as cyclosporine, whose cyclic structure resists proteases. Linear peptides of incretin size do not.

Is SNAC an active drug?

No. It is a formulation excipient. It has no GLP-1 activity of its own; it only helps the peptide survive and cross.

Why are research peptides supplied as a freeze-dried powder?

Because removing water removes the main route to hydrolysis. A lyophilised peptide stored cold and dry is far more stable than the same peptide in solution.

Research & Regulatory News

Why Peptides Cannot Normally Be Taken Orally

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-222 cited sources

A swallowed peptide faces three sequential barriers: acid hydrolysis in the stomach, enzymatic cleavage by proteases, and poor permeability across the intestinal wall because peptides are large and polar. Oral bioavailability for an unmodified peptide is typically well under one percent, which is why almost all therapeutic peptides are injected.

Key facts

Barrier 1: Gastric acid (pH ~1.5–3.5)
Barrier 2: Pepsin, trypsin, chymotrypsin, DPP-4
Barrier 3: Low permeability — large, polar molecules
Typical oral bioavailability: Well below 1% unmodified
Known workaround: Permeation enhancers such as SNAC
Alternative: Abandon the peptide backbone entirely

The three barriers in order

Acid comes first. The stomach sits around pH 1.5 to 3.5, and prolonged exposure hydrolyses peptide bonds without any enzyme involved. Enzymes come second: pepsin in the stomach, then trypsin and chymotrypsin in the small intestine, each cleaving at characteristic residues. Anything that survives both meets the third barrier, which is simple physical chemistry — peptides are large and heavily hydrogen-bonded, and the intestinal epithelium does not readily let such molecules across.

Why DPP-4 matters specifically for incretins

Dipeptidyl peptidase-4 removes the first two residues from the N-terminus of native GLP-1, and that alone inactivates it. Endogenous GLP-1 has a half-life of roughly one to two minutes as a result. Every long-acting incretin analogue is, in part, an exercise in engineering around this single enzyme — usually by substituting the residue DPP-4 recognises and by adding a fatty-acid chain that binds albumin to slow renal clearance.

How absorption enhancers work

Salcaprozate sodium, usually written SNAC, is co-formulated with oral semaglutide. It raises local pH in the immediate vicinity of the tablet, which protects the peptide from acid and pepsin, and transiently increases permeability of the gastric mucosa so some fraction of the dose crosses. It is effective but conditional: it depends on the tablet sitting in a relatively empty stomach with a small, defined volume of water, which is exactly why oral semaglutide carries fasting instructions.

The other route: stop using a peptide

The alternative to protecting a fragile molecule is designing one that was never fragile. Orforglipron has no peptide bonds, so acid and proteases have nothing to act on, and its size and polarity were optimised for permeability from the start. It needs no enhancer and carries no food or water conditions. This is why its 2026 authorisation is discussed as a formulation milestone rather than only an efficacy result.

What this means for handling research peptides

The same chemistry explains standard laboratory practice. Peptides are supplied lyophilised because water enables hydrolysis; they are reconstituted immediately before use, kept cold, and protected from repeated freeze-thaw cycles. A peptide left in solution at room temperature is subject to the same bond chemistry that defeats oral administration, only more slowly.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Do any peptides work orally without help?: Very few, and generally only small, unusually rigid ones such as cyclosporine, whose cyclic structure resists proteases. Linear peptides of incretin size do not.
Is SNAC an active drug?: No. It is a formulation excipient. It has no GLP-1 activity of its own; it only helps the peptide survive and cross.
Why are research peptides supplied as a freeze-dried powder?: Because removing water removes the main route to hydrolysis. A lyophilised peptide stored cold and dry is far more stable than the same peptide in solution.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum